The fourth paradigm: data intensive scientific discovery - Jisc Digifest 2016Jisc
There is broad recognition within the scientific community that the emerging data deluge will fundamentally alter disciplines in areas throughout academic research. A wide variety of researchers - from scientists and engineers to social scientists and humanities researchers - will require tools, technologies, and platforms that seamlessly integrate into standard scientific methodologies and processes.
'The fourth paradigm' refers to the data management techniques and the computational systems needed to manipulate, visualize, and manage large amounts of research data. This talk will illustrate the challenges researchers will face, the opportunities these changes will afford, and the resulting implications for data-intensive researchers.
In addition, the talk will review the global movement towards open access, research repositories and open science and the importance of curation of digital data. The talk concludes with some comments on the research requirements for campus e-infrastructure and the end-to-end performance of the network.
An elderly woman, Ottilie Lundgren, was admitted to the hospital with fever, cough, and muscle aches. Her condition deteriorated and she was found to have inhalational anthrax. This prompted an investigation that found additional cases of anthrax, some of which were fatal. The document discusses the challenges of using information technologies and decision support systems to aid in the response to bioterrorism events by providing surveillance, diagnosis, management, and communication capabilities. It reviews various existing systems but finds that few have been properly evaluated and none were designed specifically for bioterrorism response. Future work is needed to develop integrated systems and evaluate their ability to improve early detection and response.
The document discusses trends in clinical research and career prospects. It provides an overview of clinical trials, including what they are, their guiding principles, and a brief history highlighting the first clinical trial in 1747. It then covers topics like good clinical practice guidelines, the various phases of clinical trials, and career options in clinical research. Emerging trends are also summarized, such as the movement from paper-based to electronic data collection and regulatory submissions. Overall, the document offers a high-level introduction to clinical research processes, guidelines, and associated career paths.
The document discusses key considerations for big data aspects of precision medicine. It outlines 10 points regarding potential disparities in data capture, the importance of active participant involvement, ensuring enough statistical power through validation studies, exploiting network effects to connect multiple data sets while maintaining privacy, the need for third party access and usability of data, allowing imperfect initial data release, keeping data fresh over time, and leaving open questions for other researchers.
The Uneven Future of Evidence-Based MedicineIda Sim
An Apple ResearchKit study enrolled 22,000 people in five days. A
study claims that Twitter can be used to identify depressed patients. A computer program crunches genomic data, the published literature, and electronic health record data to guide cancer treatment. The pace, the data sources, and the methods for generating medical evidence are changing radically. What will — what should — evidence-based medicine look like in a faster, personalized, data-dense tomorrow?
- Presented as the 3rd Annual Cochrane Lecture, October 2015 in Vienna, Austria.
Finding and Accessing Human Genomics DatasetsManuel Corpas
This document summarizes a workshop about finding and accessing human genomic datasets. The workshop covered various data sources such as public repositories, case studies on accessing data from the University of Cambridge, and a demonstration of the Repositive platform which aims to simplify accessing genomic data through a single search. Hands-on sessions allowed participants to search for genomic data themes in small groups using Repositive and report their results. Overall the workshop aimed to educate researchers on challenges of accessing genomic data and introduce Repositive as a tool to help address fragmentation and simplify the workflow for discovering and accessing genomic datasets.
The fourth paradigm: data intensive scientific discovery - Jisc Digifest 2016Jisc
There is broad recognition within the scientific community that the emerging data deluge will fundamentally alter disciplines in areas throughout academic research. A wide variety of researchers - from scientists and engineers to social scientists and humanities researchers - will require tools, technologies, and platforms that seamlessly integrate into standard scientific methodologies and processes.
'The fourth paradigm' refers to the data management techniques and the computational systems needed to manipulate, visualize, and manage large amounts of research data. This talk will illustrate the challenges researchers will face, the opportunities these changes will afford, and the resulting implications for data-intensive researchers.
In addition, the talk will review the global movement towards open access, research repositories and open science and the importance of curation of digital data. The talk concludes with some comments on the research requirements for campus e-infrastructure and the end-to-end performance of the network.
An elderly woman, Ottilie Lundgren, was admitted to the hospital with fever, cough, and muscle aches. Her condition deteriorated and she was found to have inhalational anthrax. This prompted an investigation that found additional cases of anthrax, some of which were fatal. The document discusses the challenges of using information technologies and decision support systems to aid in the response to bioterrorism events by providing surveillance, diagnosis, management, and communication capabilities. It reviews various existing systems but finds that few have been properly evaluated and none were designed specifically for bioterrorism response. Future work is needed to develop integrated systems and evaluate their ability to improve early detection and response.
The document discusses trends in clinical research and career prospects. It provides an overview of clinical trials, including what they are, their guiding principles, and a brief history highlighting the first clinical trial in 1747. It then covers topics like good clinical practice guidelines, the various phases of clinical trials, and career options in clinical research. Emerging trends are also summarized, such as the movement from paper-based to electronic data collection and regulatory submissions. Overall, the document offers a high-level introduction to clinical research processes, guidelines, and associated career paths.
The document discusses key considerations for big data aspects of precision medicine. It outlines 10 points regarding potential disparities in data capture, the importance of active participant involvement, ensuring enough statistical power through validation studies, exploiting network effects to connect multiple data sets while maintaining privacy, the need for third party access and usability of data, allowing imperfect initial data release, keeping data fresh over time, and leaving open questions for other researchers.
The Uneven Future of Evidence-Based MedicineIda Sim
An Apple ResearchKit study enrolled 22,000 people in five days. A
study claims that Twitter can be used to identify depressed patients. A computer program crunches genomic data, the published literature, and electronic health record data to guide cancer treatment. The pace, the data sources, and the methods for generating medical evidence are changing radically. What will — what should — evidence-based medicine look like in a faster, personalized, data-dense tomorrow?
- Presented as the 3rd Annual Cochrane Lecture, October 2015 in Vienna, Austria.
Finding and Accessing Human Genomics DatasetsManuel Corpas
This document summarizes a workshop about finding and accessing human genomic datasets. The workshop covered various data sources such as public repositories, case studies on accessing data from the University of Cambridge, and a demonstration of the Repositive platform which aims to simplify accessing genomic data through a single search. Hands-on sessions allowed participants to search for genomic data themes in small groups using Repositive and report their results. Overall the workshop aimed to educate researchers on challenges of accessing genomic data and introduce Repositive as a tool to help address fragmentation and simplify the workflow for discovering and accessing genomic datasets.
NCCMT ACSRM Conducting Rapid Reviews Aug 4 2023.pdfACSRM
This webinar presents the following:
1. What are rapid reviews? How are they different from systematic reviews?
2. The rapid review process: developing topics and research questions, performing search, critical appraisal, and screening.
3. Software for rapid reviews
3. Demonstration
Genome sharing projects around the world nijmegen oct 29 - 2015Fiona Nielsen
Genome sharing projects across the world
Did you ever wonder what happened to the exponential increase in genome sequencing data? It is out there around the world and a lot of it is consented for research use. This means that if you just know where to find the data, you can potentially analyse gigabytes of data to power your research.
In this talk Fiona will present community genome initiatives, the genome sharing projects across the world, how you can benefit from this wealth of data in your work, and how you can boost your academic career by sharing and collaboration.
by Fiona Nielsen, Founder and CEO of DNAdigest and Repositive
With a background in software development Fiona pursued her career in bioinformatics research at Radboud University Nijmegen. Now a scientist-turned-entrepreneur Fiona founded DNAdigest and its social enterprise spin-out Repositive Ltd. Both the charity and company focus on efficient and ethical sharing of genetics data for research to accelerate diagnostics and cures for genetic diseases.
Why science needs open data – Jisc and CNI conference 10 July 2014Jisc
This document discusses the importance of open data in science. It provides 4 key reasons why open data is important:
1) It allows for identification of patterns in large datasets that could not be found otherwise.
2) It enables data modeling through iterative integration of initial models with observational data.
3) It facilitates deeper integration and analysis of diverse linked datasets.
4) It supports exploitation of networked sensor data through acquisition, integration, analysis and feedback.
However, open data needs to be "intelligently open" through being discoverable, accessible, intelligible, assessable and reusable to realize its full potential. Mandating such intelligent open data is important to drive an open data infrastructure ecology.
UCSF Informatics Day 2014 - Ida Sim, "Informatics Technologies: From a Data-C...CTSI at UCSF
This document discusses moving from a data-centric to a hypothesis-centric view of clinical and translational research using electronic health records and other informatics technologies. It notes that most current research is observational rather than interventional, and outlines ways informatics could better support hypothesis testing through virtual, community-based, and point-of-care clinical trials by integrating risk calculators, structured note templates, surveys, and other tools directly into clinical workflows and patient portals. The presentation calls for further developing these informatics capabilities to facilitate more interventional research at lower cost.
Clinical trial data wants to be free: Lessons from the ImmPort Immunology Dat...Barry Smith
Presentation to the Clinical and Research Ethics Seminar, Clinical and Translational Science Center, Buffalo, January 21, 2014
https://immport.niaid.nih.gov/
http://youtu.be/booqxkpvJMg
Data Science Deep Roots in Healthcare IndustryDinesh V
Data Science transforms the healthcare industry with impeccable solutions that can improve patient care through EHRs, medical imaging, drug discovery, predictive medicines and genetics and genomics.
[2.7] Practice of Data Management in Clinical Research - Barry Ruijter [3TU.D...3TU.Datacentrum
3TU.Datacentrum Symposium Research Data Management:
Funder requirements, Questions and Solutions
At this symposium the funding organisation NWO and the European Commission explained their vision, plans and requirements. Researchers from the three universities of technology shared their experiences of data management in different stages of research. And the Research Data Services team informed the audience about research data management services offered by 3TU.Datacentrum.
The 3TU.Datacentrum symposium took place at the TU Delft (26 May), University of Twente (2 June) and TU Eindhoven (11 June) for and with local researchers.
More information on: datacentrum.3tu.nl/over-3tudatacentrum/symposium-2014
Sharing and standards christopher hart - clinical innovation and partnering...Christopher Hart
Acknowledging the increasing need for cooperation and collaboration in data sharing and access. Describing the complexity that this can bring. Then describing some of the ways to simplify that.
Originally presented at Terrapin's Clinical innovation and partnering world March 8-9 2017.
http://www.terrapinn.com/conference/innovation-and-partnering/index.stm
The drug development process is lengthy, expensive and highly prescriptive. Many drug trials will fail or run into difficulties, and so there is a constant pressure for even marginal improvements. Surprisingly, many of the salient problems are concerned with "soft" or social knowledge: who are the "best" clinical investigators to work with? What other investigators might they know that they can recruit? What is their conversation in the therapeutic space?
Here we detail our experiences in mining academic literature, social networks and publications to build a social graph for figures in the drug trial space. By interrogating this graph and integrating it with text analysis of their dialogue, we hope to be able to identify key figures that can be engaged, and useful people and sites that can be recruited into clinical trials, thus making the development of new therapies more efficient.
IRIDA: A Federated Bioinformatics Platform Enabling Richer Genomic Epidemiolo...William Hsiao
Introducing BCCDC and Public Health Microbiology (PHM)
Current State of PHM
Sequence Technology Advancement -> revolution of PHM
Genomic Epidemiology
Amount of Sequence Data Produced
Need to Process the data – Introduction to IRIDA
Need of Metadata and Ontology
Software to improve data sharing
How research microbiology and PHM can joint effort
The Global Health Trials is a free, neutral network of communities of researchers, who are working together to share their knowledge about how to conduct research, so as to facilitate more research around the world and so improve health outcomes. It is for everyone, whatever your job role and wherever you are based, as long as you work in a Low or low-middle income country.
The Big Picture: The Industrial Revolutiona talk in berlin, 2008, about indus...robertstevens65
The document discusses the industrialization of biology through data production, analysis, integration and automation. It outlines how biology has industrialized data production and is beginning to industrialize data analysis. Fully integrating and joining together data, experiments and analysis through semantic knowledge bases and automated systems is presented as the next step. Examples of querying data and generating hypotheses to design new automated experiments are provided.
This document provides guidance on how to write an effective study protocol. It explains that a study protocol should describe each step of a study to ensure objectives can be achieved, the study is feasible, and crucial information is collected. Key components of a protocol include background and justification, objectives, methods, ethical considerations, project management, timetable, resources, and appendices. The document outlines these components in detail and provides examples. It also discusses common problems to avoid, such as objectives that are not well formulated or justified. The overall aim of a study protocol is to provide a clear plan for conducting the study.
The document discusses the benefits of clinical trial authors submitting supplemental materials and making raw trial data publicly available, such as enabling other researchers to verify results, test secondary hypotheses, and aid the design of future trials, while also outlining some arguments against data sharing and proposing a code of conduct for data sharing. It concludes by suggesting medical journals require data availability for publication to help address issues around researchers restricting access to trial data.
The document discusses the benefits of clinical trial authors submitting supplemental materials and making raw trial data publicly available, such as enabling other researchers to verify results, test secondary hypotheses, and aid the design of future trials, while also outlining some arguments researchers give against data sharing and proposing a code of conduct for data sharing.
Health CIO Network Webinar: Overcoming the Challenges of Clinical DocumentationNuance Healthcare EMEA
Nuance commissioned an independent research company, Ignetica, to carry out research into the Challenge of Clinical Documentation in NHS England Secondary Care Trusts (Jan to April 2015). The results are now out and have great relevance and value for Health CIO/CCIOs and other decision makers within UK Healthcare making investments in EPRs and other digital healthcare projects
Get the headlines from the research and hear how Alder Hey’s Paediatric Intensive Care Unit are overcoming some of the challenges highlighted in the research
Presented by: Frederik Brabant, CMIO, Nuance, Peter Booth, MD, Ignetica & Elaine Scott and Peter White, Nurse Leads of e-health projects at Alder Hey Paediatric Intensive Care Unit
Presented by: Frederik Brabant, CMIO, Nuance, Peter Booth, MD, Ignetica & Elaine Scott and Peter White, Nurse Leads of e-health projects at Alder Hey Paediatric Intensive Care Unit
Chaired By: Jon Hoeskma, CEO, Digital Health
Workshop - finding and accessing data - Cambridge August 22 2016Fiona Nielsen
Finding and accessing human genomic data for research
University of Cambridge, United Kingdom | Seminar Room G
Monday, 22 August 2016 from 10:00 to 12:00 (BST)
Charlotte, Nadia and Fiona presented an overview of data sources around the world where you can find genomics data for your research and gave examples of the data access application for dbGaP and EGA with specific details relevant for University of Cambridge researchers.
ClinicalCodes.org: An online repository of clinical code lists for primary ca...David Springate
This document discusses ClinicalCodes.org, an online repository for clinical code lists used in primary care database research. It outlines issues with a lack of published code lists, such as inability to validate or replicate studies and difficulty comparing studies over time as condition definitions change. ClinicalCodes.org aims to address these issues by providing a central location for researchers to upload, download, and archive code lists. This would improve research quality and allow other researchers to build upon previous work in a standardized way. Motivations for researchers to upload their code lists include validation of their work, increased citations, and a requirement by journals and funders for transparent and accessible code lists.
NCCMT ACSRM Conducting Rapid Reviews Aug 4 2023.pdfACSRM
This webinar presents the following:
1. What are rapid reviews? How are they different from systematic reviews?
2. The rapid review process: developing topics and research questions, performing search, critical appraisal, and screening.
3. Software for rapid reviews
3. Demonstration
Genome sharing projects around the world nijmegen oct 29 - 2015Fiona Nielsen
Genome sharing projects across the world
Did you ever wonder what happened to the exponential increase in genome sequencing data? It is out there around the world and a lot of it is consented for research use. This means that if you just know where to find the data, you can potentially analyse gigabytes of data to power your research.
In this talk Fiona will present community genome initiatives, the genome sharing projects across the world, how you can benefit from this wealth of data in your work, and how you can boost your academic career by sharing and collaboration.
by Fiona Nielsen, Founder and CEO of DNAdigest and Repositive
With a background in software development Fiona pursued her career in bioinformatics research at Radboud University Nijmegen. Now a scientist-turned-entrepreneur Fiona founded DNAdigest and its social enterprise spin-out Repositive Ltd. Both the charity and company focus on efficient and ethical sharing of genetics data for research to accelerate diagnostics and cures for genetic diseases.
Why science needs open data – Jisc and CNI conference 10 July 2014Jisc
This document discusses the importance of open data in science. It provides 4 key reasons why open data is important:
1) It allows for identification of patterns in large datasets that could not be found otherwise.
2) It enables data modeling through iterative integration of initial models with observational data.
3) It facilitates deeper integration and analysis of diverse linked datasets.
4) It supports exploitation of networked sensor data through acquisition, integration, analysis and feedback.
However, open data needs to be "intelligently open" through being discoverable, accessible, intelligible, assessable and reusable to realize its full potential. Mandating such intelligent open data is important to drive an open data infrastructure ecology.
UCSF Informatics Day 2014 - Ida Sim, "Informatics Technologies: From a Data-C...CTSI at UCSF
This document discusses moving from a data-centric to a hypothesis-centric view of clinical and translational research using electronic health records and other informatics technologies. It notes that most current research is observational rather than interventional, and outlines ways informatics could better support hypothesis testing through virtual, community-based, and point-of-care clinical trials by integrating risk calculators, structured note templates, surveys, and other tools directly into clinical workflows and patient portals. The presentation calls for further developing these informatics capabilities to facilitate more interventional research at lower cost.
Clinical trial data wants to be free: Lessons from the ImmPort Immunology Dat...Barry Smith
Presentation to the Clinical and Research Ethics Seminar, Clinical and Translational Science Center, Buffalo, January 21, 2014
https://immport.niaid.nih.gov/
http://youtu.be/booqxkpvJMg
Data Science Deep Roots in Healthcare IndustryDinesh V
Data Science transforms the healthcare industry with impeccable solutions that can improve patient care through EHRs, medical imaging, drug discovery, predictive medicines and genetics and genomics.
[2.7] Practice of Data Management in Clinical Research - Barry Ruijter [3TU.D...3TU.Datacentrum
3TU.Datacentrum Symposium Research Data Management:
Funder requirements, Questions and Solutions
At this symposium the funding organisation NWO and the European Commission explained their vision, plans and requirements. Researchers from the three universities of technology shared their experiences of data management in different stages of research. And the Research Data Services team informed the audience about research data management services offered by 3TU.Datacentrum.
The 3TU.Datacentrum symposium took place at the TU Delft (26 May), University of Twente (2 June) and TU Eindhoven (11 June) for and with local researchers.
More information on: datacentrum.3tu.nl/over-3tudatacentrum/symposium-2014
Sharing and standards christopher hart - clinical innovation and partnering...Christopher Hart
Acknowledging the increasing need for cooperation and collaboration in data sharing and access. Describing the complexity that this can bring. Then describing some of the ways to simplify that.
Originally presented at Terrapin's Clinical innovation and partnering world March 8-9 2017.
http://www.terrapinn.com/conference/innovation-and-partnering/index.stm
The drug development process is lengthy, expensive and highly prescriptive. Many drug trials will fail or run into difficulties, and so there is a constant pressure for even marginal improvements. Surprisingly, many of the salient problems are concerned with "soft" or social knowledge: who are the "best" clinical investigators to work with? What other investigators might they know that they can recruit? What is their conversation in the therapeutic space?
Here we detail our experiences in mining academic literature, social networks and publications to build a social graph for figures in the drug trial space. By interrogating this graph and integrating it with text analysis of their dialogue, we hope to be able to identify key figures that can be engaged, and useful people and sites that can be recruited into clinical trials, thus making the development of new therapies more efficient.
IRIDA: A Federated Bioinformatics Platform Enabling Richer Genomic Epidemiolo...William Hsiao
Introducing BCCDC and Public Health Microbiology (PHM)
Current State of PHM
Sequence Technology Advancement -> revolution of PHM
Genomic Epidemiology
Amount of Sequence Data Produced
Need to Process the data – Introduction to IRIDA
Need of Metadata and Ontology
Software to improve data sharing
How research microbiology and PHM can joint effort
The Global Health Trials is a free, neutral network of communities of researchers, who are working together to share their knowledge about how to conduct research, so as to facilitate more research around the world and so improve health outcomes. It is for everyone, whatever your job role and wherever you are based, as long as you work in a Low or low-middle income country.
The Big Picture: The Industrial Revolutiona talk in berlin, 2008, about indus...robertstevens65
The document discusses the industrialization of biology through data production, analysis, integration and automation. It outlines how biology has industrialized data production and is beginning to industrialize data analysis. Fully integrating and joining together data, experiments and analysis through semantic knowledge bases and automated systems is presented as the next step. Examples of querying data and generating hypotheses to design new automated experiments are provided.
This document provides guidance on how to write an effective study protocol. It explains that a study protocol should describe each step of a study to ensure objectives can be achieved, the study is feasible, and crucial information is collected. Key components of a protocol include background and justification, objectives, methods, ethical considerations, project management, timetable, resources, and appendices. The document outlines these components in detail and provides examples. It also discusses common problems to avoid, such as objectives that are not well formulated or justified. The overall aim of a study protocol is to provide a clear plan for conducting the study.
The document discusses the benefits of clinical trial authors submitting supplemental materials and making raw trial data publicly available, such as enabling other researchers to verify results, test secondary hypotheses, and aid the design of future trials, while also outlining some arguments against data sharing and proposing a code of conduct for data sharing. It concludes by suggesting medical journals require data availability for publication to help address issues around researchers restricting access to trial data.
The document discusses the benefits of clinical trial authors submitting supplemental materials and making raw trial data publicly available, such as enabling other researchers to verify results, test secondary hypotheses, and aid the design of future trials, while also outlining some arguments researchers give against data sharing and proposing a code of conduct for data sharing.
Health CIO Network Webinar: Overcoming the Challenges of Clinical DocumentationNuance Healthcare EMEA
Nuance commissioned an independent research company, Ignetica, to carry out research into the Challenge of Clinical Documentation in NHS England Secondary Care Trusts (Jan to April 2015). The results are now out and have great relevance and value for Health CIO/CCIOs and other decision makers within UK Healthcare making investments in EPRs and other digital healthcare projects
Get the headlines from the research and hear how Alder Hey’s Paediatric Intensive Care Unit are overcoming some of the challenges highlighted in the research
Presented by: Frederik Brabant, CMIO, Nuance, Peter Booth, MD, Ignetica & Elaine Scott and Peter White, Nurse Leads of e-health projects at Alder Hey Paediatric Intensive Care Unit
Presented by: Frederik Brabant, CMIO, Nuance, Peter Booth, MD, Ignetica & Elaine Scott and Peter White, Nurse Leads of e-health projects at Alder Hey Paediatric Intensive Care Unit
Chaired By: Jon Hoeskma, CEO, Digital Health
Workshop - finding and accessing data - Cambridge August 22 2016Fiona Nielsen
Finding and accessing human genomic data for research
University of Cambridge, United Kingdom | Seminar Room G
Monday, 22 August 2016 from 10:00 to 12:00 (BST)
Charlotte, Nadia and Fiona presented an overview of data sources around the world where you can find genomics data for your research and gave examples of the data access application for dbGaP and EGA with specific details relevant for University of Cambridge researchers.
ClinicalCodes.org: An online repository of clinical code lists for primary ca...David Springate
This document discusses ClinicalCodes.org, an online repository for clinical code lists used in primary care database research. It outlines issues with a lack of published code lists, such as inability to validate or replicate studies and difficulty comparing studies over time as condition definitions change. ClinicalCodes.org aims to address these issues by providing a central location for researchers to upload, download, and archive code lists. This would improve research quality and allow other researchers to build upon previous work in a standardized way. Motivations for researchers to upload their code lists include validation of their work, increased citations, and a requirement by journals and funders for transparent and accessible code lists.
Similar to How to use technology to improve data integrity.pptx (20)
we need to update our knowledge regarding management of endometriosis.
Which is better: medications or surgery? let's see what can this talk tell us about
what is the efficacy of Dienogest for management of endometriosis? let's see what research can tell us
Is it better that other modalities of management?
This document outlines a 4G ovarian stimulation protocol. It discusses mono follicular versus multifollicular development in ovarian stimulation for IUI and IVF/ICSI. It also discusses luteal phase support strategies, including route of progesterone administration. Recombinant FSH, HMG, and gonadotropin dose are discussed. The document concludes by discussing a business model for an IVF center located within a hospital.
This document discusses ways to reduce miscarriage rates. It begins by outlining the agenda and introducing progesterone and NIPGT (non-invasive preimplantation genetic testing) as potential approaches. It then discusses how progesterone has immunomodulatory properties and supports the luteal phase in ART cycles. Several studies are summarized that show progesterone supplementation can reduce miscarriage rates. NIPGT is introduced as a less invasive way to assess chromosomal defects in embryos compared to traditional PGT. The document concludes that while progesterone is effective for reducing miscarriage, more evidence is still needed to determine if NIPGT could help in cases of recurrent miscarriage, especially in older patients.
This document discusses the pros and cons of transferring embryos on day 5 (blastocyst stage) versus day 3. It raises questions about whether day 5 transfer should be routine practice and whether there are any adverse effects. Specifically, it notes that day 5 transfer is not suitable for all women, especially those with a limited number of embryos, and that an increased incidence of autism has been reported. It also discusses whether day 5 transfer is practical given the infrastructure needed, and whether it is really of any value if more than one embryo is being transferred. The conclusion is that day 5 transfer should only be offered for highly selected cases.
- There is consensus that submucosal fibroids interfere with fertility and should be removed in infertile patients, regardless of size or symptoms. Subserosal fibroids do not impact fertility.
- The impact of intramural fibroids on fertility is still uncertain. Some studies show they may reduce clinical pregnancy and increase miscarriage rates, while other studies show no effect.
- The benefits of myomectomy for interstitial or intramural fibroids are unclear, as evidence is limited and conflicting. Myomectomy may be considered for failed IVF cycles or large fibroids distorting the cavity.
- There are ongoing controversies around the impact of fibroid number, location and size,
Adenomyosis is a difficult disease to diagnose due to overlapping symptoms with other conditions like fibroids. While historically considered a disease of parous women, it is increasingly being identified in nulliparous women as well. MRI is the gold standard for diagnosis but ultrasound, especially 3D ultrasound of the junctional zone, can also provide clues. Treatment depends on patient goals and includes long acting progestins, long protocol IVF to suppress symptoms during fertility treatment, and in some cases focused ultrasound or uterine sparing surgery. More research is still needed on newer minimally invasive treatments.
How to prevent occurrence of severe ovarian hyperstimulation in IVF. Is there a way ? this talk will present a pilot randomised study that may shed the light on this
IVF will remain the solution for infertile couples. But its future will dramatically be directed to fertile couples !!!! This talk will discuss these issues
- Infertility is considered a disease by the WHO and most countries, so infertility treatment is allowed. Donor gametes and surrogacy are generally not permitted in Islam.
- Assisted reproduction technologies like IVF and PGD are allowed to help couples conceive, but third parties are not acceptable. Embryo research is only permitted using spare IVF embryos.
- While stem cells are being studied for conditions like premature ovarian failure, there is no evidence they can differentiate into eggs. The risks of stem cell therapy for fertility are still unclear. Cryopreservation and some new techniques also have uncertain religious rulings.
platelet rich plasma is being used in infertility management extensively without sound evidence of its value. In this talk, we will discuss the real impact of using PRP in IVF
This document discusses common pitfalls in infertility management and provides recommendations to avoid them. It notes that too many unnecessary investigations should be avoided, and that semen analysis guidelines have been updated. It recommends not performing procedures like tubal insufflation, D&C, or ovarian drilling without evidence of benefit. Overstimulation during ovarian induction and inappropriate drug responses are highlighted. The use of laparoscopic power morcellation is warned against due to cancer risk. While stem cells may help regenerate follicles in animal models of premature ovarian failure (POF), differentiation into human oocytes has not been achieved.
This document discusses new concepts in oral contraceptive intake, specifically the 24/4 regimen. It begins by providing background on different generations of combined oral contraceptives. It then introduces the 24/4 regimen, which contains ethinylestradiol and drospirenone over 24 days followed by 4 hormone-free days. Studies show this regimen more effectively inhibits follicular development compared to the traditional 21/7 regimen. The 24/4 regimen provides 3 extra days of anti-mineralocorticoid and antiandrogenic effects, and may reduce hormone-withdrawal symptoms. A large observational study found the 24/4 regimen with drospirenone, specifically Yaz, had the lowest contraceptive failure rates including in
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdfRahul Sen
Time-lapse embryo monitoring is an advanced imaging technique used in IVF to continuously observe embryo development. It captures high-resolution images at regular intervals, allowing embryologists to select the most viable embryos for transfer based on detailed growth patterns. This technology enhances embryo selection, potentially increasing pregnancy success rates.
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
5-hydroxytryptamine or 5-HT or Serotonin is a neurotransmitter that serves a range of roles in the human body. It is sometimes referred to as the happy chemical since it promotes overall well-being and happiness.
It is mostly found in the brain, intestines, and blood platelets.
5-HT is utilised to transport messages between nerve cells, is known to be involved in smooth muscle contraction, and adds to overall well-being and pleasure, among other benefits. 5-HT regulates the body's sleep-wake cycles and internal clock by acting as a precursor to melatonin.
It is hypothesised to regulate hunger, emotions, motor, cognitive, and autonomic processes.
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7shruti jagirdar
Unit 4: MRA 103T Regulatory affairs
This guideline is directed principally toward new Molecular Entities that are
likely to have significant use in the elderly, either because the disease intended
to be treated is characteristically a disease of aging ( e.g., Alzheimer's disease) or
because the population to be treated is known to include substantial numbers of
geriatric patients (e.g., hypertension).
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
DECLARATION OF HELSINKI - History and principlesanaghabharat01
This SlideShare presentation provides a comprehensive overview of the Declaration of Helsinki, a foundational document outlining ethical guidelines for conducting medical research involving human subjects.
Nano-gold for Cancer Therapy chemistry investigatory projectSIVAVINAYAKPK
chemistry investigatory project
The development of nanogold-based cancer therapy could revolutionize oncology by providing a more targeted, less invasive treatment option. This project contributes to the growing body of research aimed at harnessing nanotechnology for medical applications, paving the way for future clinical trials and potential commercial applications.
Cancer remains one of the leading causes of death worldwide, prompting the need for innovative treatment methods. Nanotechnology offers promising new approaches, including the use of gold nanoparticles (nanogold) for targeted cancer therapy. Nanogold particles possess unique physical and chemical properties that make them suitable for drug delivery, imaging, and photothermal therapy.
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdfOsvaldo Bernardo Muchanga
GASTROINTESTINAL INFECTIONS AND GASTRITIS
Osvaldo Bernardo Muchanga
Gastrointestinal Infections
GASTROINTESTINAL INFECTIONS result from the ingestion of pathogens that cause infections at the level of this tract, generally being transmitted by food, water and hands contaminated by microorganisms such as E. coli, Salmonella, Shigella, Vibrio cholerae, Campylobacter, Staphylococcus, Rotavirus among others that are generally contained in feces, thus configuring a FECAL-ORAL type of transmission.
Among the factors that lead to the occurrence of gastrointestinal infections are the hygienic and sanitary deficiencies that characterize our markets and other places where raw or cooked food is sold, poor environmental sanitation in communities, deficiencies in water treatment (or in the process of its plumbing), risky hygienic-sanitary habits (not washing hands after major and/or minor needs), among others.
These are generally consequences (signs and symptoms) resulting from gastrointestinal infections: diarrhea, vomiting, fever and malaise, among others.
The treatment consists of replacing lost liquids and electrolytes (drinking drinking water and other recommended liquids, including consumption of juicy fruits such as papayas, apples, pears, among others that contain water in their composition).
To prevent this, it is necessary to promote health education, improve the hygienic-sanitary conditions of markets and communities in general as a way of promoting, preserving and prolonging PUBLIC HEALTH.
Gastritis and Gastric Health
Gastric Health is one of the most relevant concerns in human health, with gastrointestinal infections being among the main illnesses that affect humans.
Among gastric problems, we have GASTRITIS AND GASTRIC ULCERS as the main public health problems. Gastritis and gastric ulcers normally result from inflammation and corrosion of the walls of the stomach (gastric mucosa) and are generally associated (caused) by the bacterium Helicobacter pylor, which, according to the literature, this bacterium settles on these walls (of the stomach) and starts to release urease that ends up altering the normal pH of the stomach (acid), which leads to inflammation and corrosion of the mucous membranes and consequent gastritis or ulcers, respectively.
In addition to bacterial infections, gastritis and gastric ulcers are associated with several factors, with emphasis on prolonged fasting, chemical substances including drugs, alcohol, foods with strong seasonings including chilli, which ends up causing inflammation of the stomach walls and/or corrosion. of the same, resulting in the appearance of wounds and consequent gastritis or ulcers, respectively.
Among patients with gastritis and/or ulcers, one of the dilemmas is associated with the foods to consume in order to minimize the sensation of pain and discomfort.
Breast cancer: Post menopausal endocrine therapyDr. Sumit KUMAR
Breast cancer in postmenopausal women with hormone receptor-positive (HR+) status is a common and complex condition that necessitates a multifaceted approach to management. HR+ breast cancer means that the cancer cells grow in response to hormones such as estrogen and progesterone. This subtype is prevalent among postmenopausal women and typically exhibits a more indolent course compared to other forms of breast cancer, which allows for a variety of treatment options.
Diagnosis and Staging
The diagnosis of HR+ breast cancer begins with clinical evaluation, imaging, and biopsy. Imaging modalities such as mammography, ultrasound, and MRI help in assessing the extent of the disease. Histopathological examination and immunohistochemical staining of the biopsy sample confirm the diagnosis and hormone receptor status by identifying the presence of estrogen receptors (ER) and progesterone receptors (PR) on the tumor cells.
Staging involves determining the size of the tumor (T), the involvement of regional lymph nodes (N), and the presence of distant metastasis (M). The American Joint Committee on Cancer (AJCC) staging system is commonly used. Accurate staging is critical as it guides treatment decisions.
Treatment Options
Endocrine Therapy
Endocrine therapy is the cornerstone of treatment for HR+ breast cancer in postmenopausal women. The primary goal is to reduce the levels of estrogen or block its effects on cancer cells. Commonly used agents include:
Selective Estrogen Receptor Modulators (SERMs): Tamoxifen is a SERM that binds to estrogen receptors, blocking estrogen from stimulating breast cancer cells. It is effective but may have side effects such as increased risk of endometrial cancer and thromboembolic events.
Aromatase Inhibitors (AIs): These drugs, including anastrozole, letrozole, and exemestane, lower estrogen levels by inhibiting the aromatase enzyme, which converts androgens to estrogen in peripheral tissues. AIs are generally preferred in postmenopausal women due to their efficacy and safety profile compared to tamoxifen.
Selective Estrogen Receptor Downregulators (SERDs): Fulvestrant is a SERD that degrades estrogen receptors and is used in cases where resistance to other endocrine therapies develops.
Combination Therapies
Combining endocrine therapy with other treatments enhances efficacy. Examples include:
Endocrine Therapy with CDK4/6 Inhibitors: Palbociclib, ribociclib, and abemaciclib are CDK4/6 inhibitors that, when combined with endocrine therapy, significantly improve progression-free survival in advanced HR+ breast cancer.
Endocrine Therapy with mTOR Inhibitors: Everolimus, an mTOR inhibitor, can be added to endocrine therapy for patients who have developed resistance to aromatase inhibitors.
Chemotherapy
Chemotherapy is generally reserved for patients with high-risk features, such as large tumor size, high-grade histology, or extensive lymph node involvement. Regimens often include anthracyclines and taxanes.
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Know the difference between Endodontics and Orthodontics.Gokuldas Hospital
Your smile is beautiful.
Let’s be honest. Maintaining that beautiful smile is not an easy task. It is more than brushing and flossing. Sometimes, you might encounter dental issues that need special dental care. These issues can range anywhere from misalignment of the jaw to pain in the root of teeth.
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...Université de Montréal
“Psychiatry and the Humanities”: An Innovative Course at the University of Montreal Expanding the medical model to embrace the humanities. Link: https://www.psychiatrictimes.com/view/-psychiatry-and-the-humanities-an-innovative-course-at-the-university-of-montreal
Lecture 6 -- Memory 2015.pptlearning occurs when a stimulus (unconditioned st...AyushGadhvi1
learning occurs when a stimulus (unconditioned stimulus) eliciting a response (unconditioned response) • is paired with another stimulus (conditioned stimulus)
Lecture 6 -- Memory 2015.pptlearning occurs when a stimulus (unconditioned st...
How to use technology to improve data integrity.pptx
1. How to use technology to
improve data integrity
Hesham Al-Inany, M.D, PhD
2. • Introduction
• Past
• Future
• Before
• During
• After
• Kasr El-Aini model
• Conclusion
Outline
3. Introduction
• The Lancet MMR autism fraud, a 1998 study that falsely claimed a link
between the measles, mumps, and rubella (MMR)
vaccine and autism.
• Publicity around the 1998 study caused a sharp decline in vaccination
uptake, leading to a number of outbreaks of measles around the
world.
• undisclosed financial conflicts of interest on P.I part. to earn up to
$43 million per year selling test kits
• was struck off the medical register
16. During conducting the trial
• Monitoring the progress
• RedCap software
• Avoid data falsification
17. But
• RedCap software for universities & academic centers
• Mainly for projects but can be applied to research papers
• Free but u have to get access from university admin
• Alternative is Google sheets
21. Preprint copy release
• Ivermectin paper scandal
• Research square platform
• detecting research misconduct
22. At time of publishing 2022
• It can be detected by statistical tools, like the chi-square test for
uniformity of digit distributions.
• check the “rightmost digits” of the collected data. The “rightmost
digit” is the digit that a number ends in. It is considered to be “the
most random digit of a number,” which means that that the numbers
that make up a data set should be uniformly distributed as in a lottery
23. Journals : Hi-Tech
• Detecting and preventing peer-review fraud
• ScholarOne Manuscripts includes a program to detect unusual
submission and peer review activity that may warrant further
investigation by the journal.
36. Lines of research : model of 1st trimester U/S
• Correlation of Maternal right ventricular function with the uteroplacental circulation in first trimester and
pregnancy outcome in women with congenital heart disease
• First trimester scan for the early detection of fetal structural anomalies: detection rates
• Fetal abnormalities associated with increased nuchal translucency versus cell-free fetal DNA
• Effectiveness of a 12-13 week scan for the early diagnosis of fetal congenital anomalies ( chromosomal and
structural )
• Caesarean scar pregnancy in first trimester, longitudinal study for detection of PAS rates
• Accuracy of Prenatal diagnosis of cardiac defects
• Increased hepatic artery flow in first early-second trimester fetuses with enlarged nuchal translucency
• Performance of the First trimester ultrasound signs of spina bifida , longitudinal study
• Fetal cranium normal and abnormal at 13 weeks
• Fetal face normal and abnormal at 13 weeks
39. Next steps
• Apply RedCap data entry for any Thesis
• Electronic archive of all thesis IPD
• Committee of Data Integrity ( Prof.Dr.AbdelHamid Attia)
40. Key : compulsory ?
• But help researchers
• Ensure facilities are available for them (unit for research
excellence)
• Save their time and money ( trained secretaries doing the job)